Navigation Links
Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer 'promising'
Date:1/15/2014

An article published in the January issue of the International Journal of Radiation Oncology, Biology and Physics reports results of the Radiation Therapy Oncology Group (RTOG) phase II clinical trial of Bevacizumab (Avastin) in addition to cisplatin and pelvic radiation for locally advanced cervical cancer. The group reports that the addition of Bevacizumab to the existing standard of care was safe and showed promising overall results. The 2- and 3- year overall survival rates were 89.8 percent and 80.2 percent, respectively.

"Cervical cancer is a huge problem worldwide, but isn't as big a problem in the United States. So in many ways it tends to become a somewhat overlooked and under-studied disease," says Tracey Schefter, MD, investigator at the University of Colorado Cancer Center, director of the Stereotactic Body Radiation Therapy program at the University of Colorado School of Medicine, and the study's lead author.

Risk factors for cervical cancer include infection with the human papilloma virus (HPV). Screening dramatically reduces both the likelihood of developing cervical cancer and the disease's mortality rate. Combined, these two factors mean that 80 percent of the world's approximately 473,000 yearly cases of cervical cancer occur in the developing world. In the United States, cervical cancer rates have dropped 74 percent over the previous 50 years, but is still diagnosed in approximately 10,000 women per year, with 3,500 deaths due to the disease.

The current phase II clinical trial enrolled 49 eligible patients from 28 institutions in the years 2006-2009. The study previously reported that Bevacizumab was safe and well-tolerated in combination with cisplatin and radiation therapy in this population. Now the group reports on the secondary efficacy endpoints at a median follow-up time of 3.8 years.

Specifically the group evaluated the addition of 10mg/kg bevacizumab every two weeks for 3 cycles during
'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. ALS patients differ on treatment choices in later phases of disease
2. Reach2HD, a Phase II study in Huntingtons disease, launched
3. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
4. Phase III trial of dapivirine ring begins in Africa: New HIV prevention approach for women
5. IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
6. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
7. JDRF announces winners of first phase of Agnes Varis Glucose-Responsive Insulin Challenge
8. Positive results from Phase 1/2 stem cell trial reported
9. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
10. Teva to present new Phase III data for QNASL® Nasal Aerosol at the 2012 ACAAI Meeting
11. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer 'promising'
(Date:4/22/2014)... April 22, 2014: The Association for Molecular Pathology ... Journal of Molecular Diagnostics on recommendations for ... and master,s levels of education. The report was ... Task Force of the AMP Training and Education ... need of educating future medical laboratory scientists appropriately ...
(Date:4/22/2014)... Hopkins scientists have found a way to block abnormal ... of atherosclerosis, the main cause of heart attacks and ... The condition develops when fat builds inside blood vessels ... greatly reducing their ability to feed oxygen-rich blood to ... series of experiments, described April 7 in the journal ...
(Date:4/22/2014)... This news release is available in German . ... species are important intracellular signaling molecules, but their mode ... key aspects of cellular function and behavior, while at ... organelles, membranes and DNA. To analyze how redox signaling ... innovative optical microscopy technique has been developed jointly by ...
(Date:4/22/2014)... help rein in massive health care spending, a new ... find ways to incentivize pharmaceutical companies and device makers ... of examining existing medical technologies and their use, a ... what drugs and medical devices get created in the ... care spending with as little loss of health as ...
(Date:4/22/2014)... we all seem to know who we say is neurotic ... isn,t unable to act but simply doesn,t want to., ... study of nearly 4,000 college students in 19 countries has ... decisions and moving forward with life. Turns out that when ... just don,t like it as much as non-neurotics. Therefore persuasive ...
Breaking Medicine News(10 mins):Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Neuroimaging: Live from inside the cell 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:Neurotics don't just avoid action: They dislike it 2
... R.I. [Brown University] -- Two years ago, Brown ... of the cancer-suppressing protein p53 and you can ... the same team reports an intriguing follow-up finding. ... lifespan-extending magic in only 14 insulin-producing cells in ...
... -- (Sept. 18, 2007) -- Biomedical engineers at The ... Houston have announced pre-clinical test results in the September ... feasibility of a smart particle insulin release system that ... releases insulin to counteract them. , Designed to mimic ...
... Sept. 20, 2007 Defects on cell-surface sugars may ... in the central nervous system of multiple sclerosis patients, ... findings also suggest that a dietary supplement similar to ... correct these defects and to treat both the short-term ...
... the University of California, San Diego (UCSD) School of ... function of one of the key proteins in all ... plays an essential role in memory formation, communication between ... called x-ray crystallography, the scientists solved the structure of ...
... scientists say , THURSDAY, Sept. 20 (HealthDay News) -- Analyzing ... identify patients with the worst cases of multiple myeloma, U.S. ... noted the team from the Myeloma Institute for Research and ... Multiple myeloma is a cancer that affects the blood plasma ...
... 20 Lehman Millet Incorporated, the,leading medical ... appointment of key hires into its strategy, ... agency attributes this steady,staff expansion to client ... as new,business assignments. Lee Stayton joins ...
Cached Medicine News:Health News:Key to longer life (in flies) lies in just 14 brain cells 2Health News:Smart insulin nanostructures pass feasibility test, UT study reports 2Health News:Cell-surface sugar defects may trigger nerve damage in multiple sclerosis patients 2Health News:UCSD study reveals the regulatory mechanism of key enzyme 2Health News:Gene Test Could Boost Myeloma Treatment 2Health News:LehmanMillet Continues Expansion with Strategic Hires 2Health News:LehmanMillet Continues Expansion with Strategic Hires 3
(Date:1/15/2014)... 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... support, China,s orthopedic instrument industry ... market size rising from 3.28 billion yuan in 2006 ...
(Date:1/15/2014)... As health officials across the Midwest warn against the widespread ... Michigan will offer free diagnostic testing for ... to administer tests and, in some cases, fill the matching ... the study. The Grand Rapids, Mich. ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... of Higher Doses to Further Reduce Antibodies,to ... /PRNewswire-FirstCall/ -- La Jolla,Pharmaceutical Company today announced ... placebo-controlled,randomized Phase 3 trial of Riquent(R) (abetimus ... ("lupus" or "SLE").,Analyses of interim antibody data ...
... Animal Data Shows Prolonged Survival AND ... 2007 /PRNewswire-FirstCall/ --,ImmuneRegen BioSciences, a wholly-owned ... today that ongoing analysis of,data acquired ... has,revealed evidence that ImmuneRegen's developmental stage ...
Cached Medicine Technology:La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6La Jolla Pharmaceutical Announces Positive Interim Antibody Results,From Riquent Lupus Phase 3 Trial 7IR BioSciences Announces Data Demonstrating Radilex Stimulation of,Stem Cells Results in Hematopoietic Recovery Following Lethal,Irradiation 2IR BioSciences Announces Data Demonstrating Radilex Stimulation of,Stem Cells Results in Hematopoietic Recovery Following Lethal,Irradiation 3IR BioSciences Announces Data Demonstrating Radilex Stimulation of,Stem Cells Results in Hematopoietic Recovery Following Lethal,Irradiation 4IR BioSciences Announces Data Demonstrating Radilex Stimulation of,Stem Cells Results in Hematopoietic Recovery Following Lethal,Irradiation 5
The Trans-Blot transfer cell, used with the included PowerPac 200 power supply, performs efficient, high-intensity electrophoretic transfers. The Trans-Blot cell offers many advantages....
... specifically designed to work with the EC120 ... a small tank blotter that incorporates the ... buffer requirements and fast transfer rates), with ... blotting such as arcing and buffer depletion. ...
... Semi-Dry Blotting System. 20cm x ... Southern gels reliably and quickly. The ... are durable and corrosion free. These ... excellent transfers. Also available in 35cm ...
... SD semi-dry transfer cell allows ... Using a platinum-coated titanium plate ... stainless steel plate as the ... transfers in a horizontal configuration ...
Medicine Products: